Transgene SA - Product Pipeline Review - 2015 Summary Global Markets Direct's, 'Transgene SA - Product Pipeline Review - 2015', provides an overview of the Transgene SA's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Transgene SA's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Transgene SA including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Transgene SA's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Transgene SA's pipeline products Reasons to Buy - Evaluate Transgene SA's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Transgene SA in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Transgene SA's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Transgene SA and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Transgene SA - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Explore the dormant and discontinued projects of Transgene SA and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents
Table of Contents
2 List of Tables 4 List of Figures 4 Transgene SA Snapshot 5 Transgene SA Overview 5 Key Information 5 Key Facts 5 Transgene SA - Research and Development Overview 6 Key Therapeutic Areas 6 Transgene SA - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Pipeline Products - Partnered Products 10 Partnered Products/Combination Treatment Modalities 11 Transgene SA - Pipeline Products Glance 12 Transgene SA - Clinical Stage Pipeline Products 12 Phase II Products/Combination Treatment Modalities 12 Phase I Products/Combination Treatment Modalities 13 Transgene SA - Early Stage Pipeline Products 14 Preclinical Products/Combination Treatment Modalities 14 Transgene SA - Drug Profiles 15 TG-4010 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 pexastimogene devacirepvec 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 TG-1042 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 TG-4001 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 MVA-TB 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 TG-1050 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 TG-3003 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 TG-6002 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 Transgene SA - Pipeline Analysis 27 Transgene SA - Pipeline Products by Target 27 Transgene SA - Pipeline Products by Route of Administration 28 Transgene SA - Pipeline Products by Molecule Type 29 Transgene SA - Pipeline Products by Mechanism of Action 30 Transgene SA - Recent Pipeline Updates 31 Transgene SA - Dormant Projects 41 Transgene SA - Discontinued Pipeline Products 42 Discontinued Pipeline Product Profiles 42 TG-1042 42 Transgene SA - Locations And Subsidiaries 43 Head Office 43 Other Locations & Subsidiaries 43 Appendix 44 Methodology 44 Coverage 44 Secondary Research 44 Primary Research 44 Expert Panel Validation 44 Contact Us 44 Disclaimer 45
List of Tables
Transgene SA, Key Information 5 Transgene SA, Key Facts 5 Transgene SA - Pipeline by Indication, 2015 7 Transgene SA - Pipeline by Stage of Development, 2015 8 Transgene SA - Monotherapy Products in Pipeline, 2015 9 Transgene SA - Partnered Products in Pipeline, 2015 10 Transgene SA - Partnered Products/ Combination Treatment Modalities, 2015 11 Transgene SA - Phase II, 2015 12 Transgene SA - Phase I, 2015 13 Transgene SA - Preclinical, 2015 14 Transgene SA - Pipeline by Target, 2015 27 Transgene SA - Pipeline by Route of Administration, 2015 28 Transgene SA - Pipeline by Molecule Type, 2015 29 Transgene SA - Pipeline Products by Mechanism of Action, 2015 30 Transgene SA - Recent Pipeline Updates, 2015 31 Transgene SA - Dormant Developmental Projects,2015 41 Transgene SA - Discontinued Pipeline Products, 2015 42 Transgene SA, Subsidiaries 43
List of Figures
Transgene SA - Pipeline by Top 10 Indication, 2015 7 Transgene SA - Pipeline by Stage of Development, 2015 8 Transgene SA - Monotherapy Products in Pipeline, 2015 9 Transgene SA - Partnered Products in Pipeline, 2015 10 Transgene SA - Pipeline by Top 10 Target, 2015 27 Transgene SA - Pipeline by Top 10 Route of Administration, 2015 28 Transgene SA - Pipeline by Top 10 Molecule Type, 2015 29 Transgene SA - Pipeline Products by Top 10 Mechanism of Action, 2015 30
Global microcontroller market is estimated to be valued at USD 26.9 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing demand in key application areas such as automotive, consumer electronics and healthcare is expected toRead More...
Global agricultural films market size is anticipated to reach USD 10.5 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing need to raise agricultural productivity, in order to meet surplus demand by growing population iRead More...
Global data center UPS market size is estimated to reach USD 5.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Declining tolerance levels pertaining to data loss along with amplifying acceptance of cloud computing is likelyRead More...
Global LCP (Liquid Crystal Polymer) industry is forecasted to reach USD 1.23 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing trend towards developing militarized components and connectors are likely to drive the demandRead More...
Global non halogenated flame retardants market size is anticipated to be valued at USD 2.54 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing safety materials demand owing to low heat & smoke emission properties in cRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.